EUVIMEDEUVIMED entdecken
Kohortenstudie

Increased Incidence of COVID ‐19 Infection in Atopic Dermatitis Patients: A Real‐World Cohort Study With Risk Factor Analysis

Meng-Han Shen, Hsin-Yu An, Chia-Lung Shih iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17738 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Meng-Han Shen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, COVID-19. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a common chronic inflammatory skin condition. COVID‐19, a novel coronavirus, sparked a global pandemic in late 2019. The connection between AD and COVID‐19 infection remains unclear; moreover, the risk factors for COVID‐19 infection among AD patients have not been thoroughly explored. The TriNetX Research Network was used to investigate the association between AD and COVID‐19 infection. A logistic regression was used to estimate the odds ratio (OR) between AD and COVID‐19 infection. We found that AD patients had a significantly higher odds of COVID‐19 infection compared to individuals without AD, regardless of age and sex. For risk factors among AD patients, we found that the younger age group (age ≤ 20 years) had significantly lower odds of COVID‐19 infection when compared with old‐age groups, while no significant difference in odds of COVID‐19 infection between females and males was observed. Hypertension, diabetes mellitus, asthma, ischemic heart disease, and overweight and obesity significantly increased the odds of COVID‐19 infection, respectively. AD patients treated by dupilumab resulted in lower odds of COVID‐19 infection compared to those treated by methylprednisolone, prednisone, or prednisolone. In conclusion, patients with AD had increased risk of COVID‐19 infection across all age groups and sexes. Younger individuals demonstrated higher infection risks. Certain comorbidities further increased the risk of COVID‐19 infection in AD patients. Treatment with dupilumab was associated with a lower risk of COVID‐19 infection in AD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCOVID-19HumansMaleFemaleRisk FactorsAdultMiddle AgedIncidenceYoung AdultSARS-CoV-2AgedAntibodies, Monoclonal, HumanizedAge FactorsAdolescentSex FactorsCohort Studies

Stichwörter der Autor:innen

COVID‐19atopic dermatitisdupilumabrisk factor

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
  • Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Depatment of Family Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Clinical Research Center, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

ORCID-Profile: Chia-Lung Shih

Zitieren

APA

Shen, M. H., An, H. Y., & Shih, C. L. (2025). Increased Incidence of COVID ‐19 Infection in Atopic Dermatitis Patients: A Real‐World Cohort Study With Risk Factor Analysis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17738

Vancouver

Shen MH, An HY, Shih CL. Increased Incidence of COVID ‐19 Infection in Atopic Dermatitis Patients: A Real‐World Cohort Study With Risk Factor Analysis. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17738

BibTeX
@article{Shen2025,
  author = {Shen, Meng-Han and An, Hsin-Yu and Shih, Chia-Lung},
  title = {Increased Incidence of COVID ‐19 Infection in Atopic Dermatitis Patients: A Real‐World Cohort Study With Risk Factor Analysis},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17738}
}
Kostenlos starten →